Blockbuster weight-loss and diabetes drugs such as Ozempic and Mounjaro may offer benefits beyond the waistline, with growing evidence suggesting they could influence brain health. The medications, known as GLP-1 receptor agonists, have been linked in observational studies to a lower risk of dementia, prompting scientists to investigate whether they help preserve memory and thinking abilities. However, major clinical trials found that semaglutide, the active ingredient in Ozempic, did not slow the progression of Alzheimer's disease, tempering early enthusiasm about a direct treatment effect.
Researchers suspect the drugs may be most effective at protecting cognition in people with obesity or diabetes, particularly when taken before cognitive problems appear. The emerging picture suggests a nuanced role for GLP-1 medications in brain health rather than a clear dementia therapy. Scientists caution that further trials are needed to determine which patients might benefit and at what stage of life. The findings add to a broader debate over the expanding uses of these increasingly popular drugs, which have already transformed the treatment of obesity and type 2 diabetes worldwide.
Independent reporting synthesized from primary wires and global correspondents.